glp 1 ra medicine Research shows GLP-1 drugs are effective but complex it’s the perfect companion for anyone using GLP Glucagon-Like Peptide 1 Receptor Agonists

Bloating is one of the most common side effects of GLP-1 injection treatments, including semaglutide (Wegovy) and tirzepatide (Mounjaro)

Ethics declarations Competing interests E.M

In this context, the promising launch data of the Wegovy pill hints at early demand elasticity and it is running ahead of historical precedent

Beyond weight reduction, the same trial reported several additional metabolic outcomes as secondary or exploratory endpoints: Improved glycaemic control reductions in HbA1c levels were observed in participants with type 2 diabetes in a separate Phase 2 cohort [3] [4] Reduced waist circumference suggesting a decrease in visceral (abdominal) fat, which is associated with cardiovascular risk Improvements in lipid profiles including reductions in triglycerides Potential signal for benefit in metabolic-associated steatotic liver disease (MASLD) based on the glucagon receptor's proposed role in hepatic fat metabolism

These usually improve as the medication continues to clear from the body